Noninvasive Hair Rejuvenation

This systematic review found that low-level light/laser therapy showed a positive effect in treating male and female pattern hair loss without side effects, as reported by all analyzed randomized controlled trials.

This review indicates that most studies reported positive effects of platelet-rich plasma injections for treating androgenic alopecia, with no major side effects, suggesting it may be a safe alternative to Minoxidil and Finasteride.

In this study, microneedling with minoxidil solution showed a significantly better response in treating male androgenetic alopecia compared to microneedling with a hair multivitamin solution.

This study reviewed clinical trials and found that low-level laser therapy significantly increased hair diameter or density in both men and women with pattern hair loss compared to a sham device, though the involvement of industry relationships in some studies suggests cautious interpretation.

This systematic review suggests that topical ketoconazole may improve hair regrowth and thickness in both animal and human studies for androgenetic alopecia, but further randomized controlled trials are needed.

This meta-analysis found that dutasteride was more effective than finasteride in increasing hair count and improving photographic assessments for men with androgenetic alopecia, while both drugs had similar rates of sexual dysfunction-related adverse effects.

In this study, the authors reported that among patients with androgenetic alopecia, treatment with minoxidil 5% lotion combined with PRP and microneedling resulted in better hair growth and higher satisfaction compared to other treatment groups.

This review found that three monthly PRP injections improved hair density in patients with androgenetic alopecia compared to placebo, but more rigorous studies are needed for broader dermatological applications.

This review found that while finasteride may improve female pattern hair loss and hirsutism in women, more long-term studies are needed to optimize its use and assess potential consequences.

This paper discusses the first reported case of post-finasteride syndrome in a long-term dermatotrichology setting, occurring in a 25-year-old male after dutasteride treatment, and highlights possible links to mental health disorders.

This study found that a topical combination of 0.25% finasteride and 3% minoxidil may increase hair diameter more effectively than 3% minoxidil alone in postmenopausal women with female pattern hair loss.

This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.

This study found that combining microneedling with topical minoxidil was more effective than minoxidil alone in increasing hair count and improving patient satisfaction for men with androgenetic alopecia, though the cosmetic impact was not significant.

This study found that low-level laser therapy may significantly improve androgenic alopecia in both men and women, either alone or alongside treatments like minoxidil and finasteride.

This study reported that once-daily treatment with oral minoxidil and spironolactone for 12 months reduced hair loss severity and hair shedding in women with pattern hair loss, with generally mild side effects, though results came from an uncontrolled, observational pilot study.

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.

This review discusses the physiology and potential hormonal mechanisms involved in female pattern hair loss, as well as the current hormonal and hormone-modifying treatments available, but reports no new research findings.

This study found that platelet-rich plasma did not significantly improve hair mass index or hair count in women with female androgenetic alopecia, though some patients perceived benefits in hair quality.

In this study of men with androgenetic alopecia, dutasteride was shown to be more effective than finasteride in increasing hair count and reversing hair miniaturization over 24 weeks, with both treatments displaying similar side effect profiles.

This study found that platelet-rich plasma significantly increased hair density and anagen hair proportions in androgenetic alopecia patients, suggesting potential as an adjuvant therapy.

This study found that 5% minoxidil topical foam was effective in stabilizing hair density and scalp coverage in men with moderate androgenetic alopecia over 104 weeks, with good safety and tolerability.

This study found that oral minoxidil 5 mg daily significantly improves hair growth in men with androgenetic alopecia, although common side effects include hypertrichosis and pedal edema.

This study suggests that dutasteride may be a viable alternative for Korean men with androgenetic alopecia who do not respond to finasteride, as it improved hair density and thickness in most participants.

This review discusses the role of Prostaglandin D2 and its synthase in androgenetic alopecia but reports no new clinical findings, suggesting pathways for future therapeutic development.

This article reviews emerging treatments for androgenetic alopecia, including topical 5-alpha-reductase inhibitors and prostaglandin modulators, but reports no clinical results and calls for further efficacy evidence, especially for PRP.

This review discusses the use of platelet-rich plasma in cosmetic surgery, highlighting its expanding applications and promising potential in aesthetic treatments, but reports no new empirical findings.

This study found that adding microneedling to minoxidil treatment significantly improved hair growth in men with androgenetic alopecia compared to minoxidil alone across all assessed measures.

This study found that 5 mg/day oral finasteride was effective and safe for improving hair outcomes in normoandrogenic postmenopausal women with androgenetic alopecia over 18 months.

This article discusses the development of an evidence-based guideline for treating androgenetic alopecia and reports no new research results.

In this study, latanoprost significantly increased hair density in young men with mild androgenetic alopecia after 24 weeks, suggesting it may stimulate hair follicle activity and treat hair loss.

This study found that daily oral finasteride may increase hair count and improve hair appearance assessments in men with androgenetic alopecia, but it also appears to raise the risk of sexual dysfunction.

This study suggests that 5 mg/day oral finasteride may increase hair density and thickness in normoandrogenic Asian women with female pattern hair loss over 12 months.

This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.

In this study, platelet plasma growth factors from patients' autologous plasma improved follicular unit yield in baldness surgery by 15.1% compared to control areas.

This study found that 88% of women with female pattern hair loss who received oral antiandrogens saw no progression or improvement in their condition.

This paper suggests that ketoconazole 2% shampoo may enhance finasteride's effectiveness in treating androgenetic alopecia by more completely inhibiting the dihydrotestosterone pathway.

In this study, the researchers did not confirm previously reported links between AGA and smoking or benign prostatic hypertrophy, but found potential associations with alcohol consumption and lean body mass at age 21 that merit further investigation.

This review discusses the genetic factors contributing to androgenetic alopecia and highlights the potential for developing more effective therapies based on recent discoveries, but reports no new clinical results.

This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.

In this study, finasteride 1 mg/day for 12 months did not improve hair growth or slow hair thinning in postmenopausal women with androgenetic alopecia compared to placebo.

Finasteride 1mg helps reverse hair miniaturization in men and postmenopausal women.

This study found that oral finasteride 1 mg/day promotes hair growth and prevents further hair loss in a significant proportion of men with male pattern hair loss over two years.

This study found that 2% ketoconazole shampoo improved hair density and anagen follicle proportion in androgenic alopecia similarly to minoxidil treatment, suggesting a potential role for Malassezia in inflammation.

This study reported that a 0.005% finasteride solution may encourage hair regrowth and reduce balding areas in patients with androgenic alopecia, without significant absorption or adverse effects.

This study found that androgenetic alopecia causes significant psychological distress, particularly in women, who exhibit a more negative body image and less adaptive functioning compared to controls.

Hair loss can cause low self-esteem, anxiety, and depression in men.

This study found that both 2% and 3% minoxidil resulted in a significant increase in hair counts for participants with androgenetic alopecia over 12 months.

Minoxidil increases blood flow in balding scalps, possibly reversing hair loss.

Minoxidil effectively controls blood pressure in severe cases, but has serious side effects and causes hair growth in women.

This article presents a classification system for stages of female-pattern androgenetic alopecia to aid early diagnosis and mentions existing systems for rare male-pattern cases, but reports no new clinical results.